Cover ImageSALE
Market Research Report

Global Krabbe Disease Treatment Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 603594
Published Content info 104 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Krabbe Disease Treatment Market 2018-2022
Published: February 5, 2018 Content info: 104 Pages
Description

About Krabbe Disease Treatment

Krabbe disease is a rare inherited genetic disorder that affects the nervous system. It is usually caused by the deficiency of the galactosylceramidase (GLC) enzyme. The disease is inherited in an autosomal recessive pattern.

Technavio's analysts forecast the global krabbe disease treatment market to grow at a CAGR of 7.24% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global krabbe disease treatment market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Krabbe Disease Treatment Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis

Market driver

  • Special drug designation
  • For a full, detailed list, view our report

Market challenge

  • Limited patient pool for clinical trials
  • For a full, detailed list, view our report

Market trend

  • Emergence of pharmacological chaperone therapy
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR20609

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline
  • Types of Krabbe disease

PART 05: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing
  • Market size and forecast

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY THERAPY

  • Segmentation by therapy
  • Comparison by therapy
  • Global Krabbe disease treatment market by anticonvulsants
  • Global Krabbe disease treatment market by muscle relaxants
  • Global Krabbe disease treatment market by HSCT
  • Global Krabbe disease treatment market by others
  • Market opportunity by therapy

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Krabbe disease treatment market in Americas
  • Krabbe disease treatment market in EMEA
  • Krabbe disease treatment market in APAC
  • Key leading countries
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • Emergence of pharmacological chaperone therapy
  • Gene technology in therapy

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis

PART 17: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Types of Krabbe disease
  • Exhibit 02: Parent market
  • Exhibit 03: Global rare diseases treatment market: Segmentation
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition: Inclusions and exclusions checklist
  • Exhibit 07: Market size
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global Krabbe disease treatment market 2017-2022 ($ millions)
  • Exhibit 10: Global Krabbe disease treatment market: Year over year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Pipeline landscape by development phase
  • Exhibit 19: Key clinical trials for global Krabbe disease treatment market
  • Exhibit 20: Global Krabbe disease treatment market by therapy 2017-2022 (% share)
  • Exhibit 21: Comparison by therapy
  • Exhibit 22: Global Krabbe disease treatment market by anticonvulsants 2017-2022 ($ millions)
  • Exhibit 23: Global Krabbe disease treatment market by anticonvulsants: Year over year growth 2018-2022 (%)
  • Exhibit 24: Global Krabbe disease treatment market by muscle relaxants 2017-2022 ($ millions)
  • Exhibit 25: Global Krabbe disease treatment market by muscle relaxants: Year over year growth 2018-2022 (%)
  • Exhibit 26: Global Krabbe disease treatment market by HSCT 2017-2022 ($ millions)
  • Exhibit 27: Global Krabbe disease treatment market by HSCT: Year over year growth 2018-2022 (%)
  • Exhibit 28: Global Krabbe disease treatment market by others 2017-2022 ($ millions)
  • Exhibit 29: Global Krabbe disease treatment market by others: Year over year growth 2018-2022 (%)
  • Exhibit 30: Market opportunity by therapy
  • Exhibit 31: Customer landscape
  • Exhibit 32: Global Krabbe disease treatment market by region 2017-2022 (% share)
  • Exhibit 33: Regional comparison
  • Exhibit 34: Krabbe disease treatment market in Americas 2017-2022 ($ millions)
  • Exhibit 35: Krabbe disease treatment market in Americas: Year over year growth 2018-2022 (%)
  • Exhibit 36: Krabbe disease treatment market in EMEA 2017-2022 ($ millions)
  • Exhibit 37: Krabbe disease treatment market in EMEA: Year over year growth 2018-2022 (%)
  • Exhibit 38: Krabbe disease treatment market in APAC 2017-2022 ($ millions)
  • Exhibit 39: Krabbe disease treatment market in APAC: Year over year growth 2018-2022 (%)
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Some long-term complications in HSCT patients
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: GlaxoSmithKline: Overview
  • Exhibit 49: GlaxoSmithKline: Business segments
  • Exhibit 50: GlaxoSmithKline: Organizational developments
  • Exhibit 51: GlaxoSmithKline: Geographic focus
  • Exhibit 52: Johnson & Johnson: Segment focus
  • Exhibit 53: GlaxoSmithKline: Key offerings
  • Exhibit 54: GlaxoSmithKline: Key customers
  • Exhibit 55: Johnson & Johnson: Overview
  • Exhibit 56: Johnson & Johnson: Business segments
  • Exhibit 57: Johnson & Johnson: Organizational developments
  • Exhibit 58: Johnson & Johnson: Geographic focus
  • Exhibit 59: Johnson & Johnson: Segment focus
  • Exhibit 60: Johnson & Johnson: Key offerings
  • Exhibit 61: Johnson & Johnson: Key customers
  • Exhibit 62: Novartis: Overview
  • Exhibit 63: Novartis: Business segments
  • Exhibit 64: Novartis: Organizational developments
  • Exhibit 65: Novartis: Geographic focus
  • Exhibit 66: Novartis: Segment focus
  • Exhibit 67: Novartis: Key offerings
  • Exhibit 68: Novartis: Key customers
Back to Top